Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.
Anup Malani, PhD
Advertisement
Articles by Anup Malani, PhD
Advertisement
Latest Updated Articles
- Representativeness of Dipeptidyl-Peptidase-4 Inhibitor Cardiovascular Outcomes Trials
Published: September 20th 2016 | Updated:
Advertisement
Advertisement
